NMTC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
2.0M
+6.0%
1.9M
-35.6%
2.9M
-49.6%
5.7M
+238.5%
1.7M
Cost of Revenue
790.5K
-9.3%
871.8K
-34.2%
1.3M
+9.3%
1.2M
+55.2%
781.2K
Gross Profit
1.2M
+19.4%
990.3K
-36.8%
1.6M
-65.4%
4.5M
+395.0%
914.8K
Operating Expenses
3.6M
+6.5%
3.4M
+3.4%
3.3M
-44.5%
5.9M
+110.6%
2.8M
R&D
1.4M
-2.9%
1.5M
+5.6%
1.4M
+24.3%
1.1M
-5.5%
1.2M
SG&A
2.2M
+13.7%
1.9M
+1.8%
1.9M
+5.8%
1.8M
+10.1%
1.6M
Operating Income
-2424312
-1.1%
-2397197
-40.4%
-1707307
-24.5%
-1371064
+27.3%
-1886600
EBITDA
-2377310
-1.7%
-2337168
-42.4%
-1641784
-25.6%
-1306740
+28.2%
-1820006
Net Income
-2006331
+15.8%
-2382022
-65.7%
-1437890
+11.2%
-1619221
-7.9%
-1500868
EPS (Basic)
$-0.23
+17.9%
$-0.28
+74.1%
$-1.08
-116.0%
$-0.50
-163.2%
$-0.19
EPS (Diluted)
$-0.28
+0.0%
$-0.28
+74.1%
$-1.08
-116.0%
$-0.50
-163.2%
$-0.19
Shares (Diluted)
8.7M
+3.0%
8.5M
+506.9%
1.4M
-56.8%
3.2M
-60.1%
8.1M
NeuroOne Medical Technologies (NMTC) โ€” Financials